A Agilent Technologies Inc.

Agilent Introduces Groundbreaking UV-Vis Spectrophotometer for Pharmaceutical, Biomedical, and Academic Laboratories

(NYSE: A) today introduced the Cary 3500 UV-Vis system, an innovative spectrophotometer designed to help life science, pharma and biopharma research communities simplify their analyses, optimize laboratory productivity, and ultimately help bring new therapeutics to market faster. Agilent will showcase the Cary 3500 UV-Vis system at analytica China, being held October 31 – November 2, 2018, in Shanghai, China.

Global growth in the development of biological drugs is leading to the evolution of many new biological entities (NBEs). Before these NBEs are adapted into therapeutics, laboratories must accurately characterize each new product and continuously monitor the quality of these products throughout the development process.

“The Agilent Cary 3500 provides a critical tool that allows laboratories to do this more quickly and accurately than is currently possible,” said Phil Binns, vice president, and general manager of Agilent's Spectroscopy division. “Our spectroscopy unit drew upon 70 years of insight and customer collaborations to create a faster, more robust system—with a lower cost of ownership.”

He noted that the Cary 3500 represents the first significant advancement in UV-Vis architecture in decades.

The new system enables laboratories to make substantial gains in efficiency as it can run multiple experiments simultaneously, allowing labs to obtain more results in the same amount of time—and it also extends the opportunity to design experiments in ways that have not been possible before.

The Cary 3500 harnesses the power of a state-of-the-art software platform and a fast and powerful Xenon flash lamp that is redefining UV-Vis spectrophotometry. Indeed, the system’s rapid, accurate, temperature control permits temperature experiments at ramp rates previously thought to be unattainable, providing more reliable and robust measurements.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,500 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to our . Follow Agilent on , , and .

EN
01/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Agilent Technologies, Inc.: Key facts and statistics - fiscal 2025

A summary company profile, detailing Agilent Technologies, Inc.’s business operations and financial highlights.

Agilent Technologies, Inc. - October 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Agilent Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its low financial leverage, against its high proportion of revenue from costly equipment sales, which has exposure to cyclical demand fluctuations

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 December 2025 in which we reassessed the appropriateness of the ratings in th...

Agilent Technologies Inc: 1 director

A director at Agilent Technologies Inc sold 2,600 shares at 149.812USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch